Finasteride and Mental health: A Closer Look at the Risks

The European Pharmaceutical Agency (EMA), through its Pharmacovigilance Risk Assessment Committee (PRAC), has concluded a thorough review of finasteride, a medication commonly used to treat hair loss and benign prostatic hyperplasia. The review confirmed a potential link between finasteride intake and the occurrence of suicidal thoughts. While the precise frequency of this side effect remains undetermined,the EMA is taking steps to enhance patient safety through clearer warnings and improved information.

Enhanced Warnings for Patients

The PRAC’s findings have prompted a revision of product information for finasteride tablets.Manufacturers will now provide more explicit warnings regarding the potential for depressed moods, depression, and suicidal thoughts. This move aims to ensure that patients are fully aware of the possible psychological risks associated wiht the medication.

To further support patients, each package of 1 mg finasteride will include a patient card. This card will outline potential risks and provide clear recommendations for action should side effects arise. This initiative is designed to empower patients to make informed decisions about their treatment and seek timely medical assistance if needed.

Sexual Dysfunction and Depressive Symptoms

Along with psychological risks, the EMA is also emphasizing the importance of clearly communicating potential sexual side effects, such as reduced libido and erectile dysfunction. according to the EMA, these side effects can contribute to the progress of depressive symptoms.Patients experiencing such symptoms are strongly encouraged to seek medical advice.

Patients who observe corresponding symptoms should also take advantage of medical help.

Dutasteride: Similar Precautions

While a definitive link between dutasteride and suicidal thoughts has not been established, the EMA security committee is taking a precautionary approach. Product information for dutasteride will be updated to include warnings about potential mood swings. Dutasteride is approved for treating benign prostatic enlargement in adult men and is sometimes used off-label for androgenetic alopecia.

It’s important to note that the EMA has found no new information warranting changes to the existing product information for finasteride sprays.

Data behind the Decision

The EMA’s decision is based on a thorough analysis of data from various sources, including clinical studies, the European Eudravigilance database, case reports from medical literature, and feedback from patients, relatives, and doctors. The analysis identified 325 relevant cases of suicidal ideation, with 313 linked to finasteride and 13 to dutasteride. A single case involved both active ingredients. The majority of affected patients where being treated for hair loss.

These reported cases were assessed in relation to an estimated overall exposure of approximately 270 million patient years for finasteride and 82 million for dutasteride. Despite these risks, the EMA maintains that the benefits of finasteride and dutasteride outweigh the potential dangers for all approved uses.

Ixchiq Chikungunya Vaccine Under Review: Safety Concerns in Older Adults

The EMA security committee is also scrutinizing the Chikungunya vaccine Ixchiq following reports of serious side effects in older individuals after vaccination. This review highlights the importance of ongoing pharmacovigilance and the need to adapt recommendations based on real-world data.

Chikungunya: A Global Health Threat

Chikungunya is a mosquito-borne viral disease prevalent in tropical and subtropical regions. Symptoms typically include high fever, severe joint pain, headache, muscle pain, and rash. While most patients recover within a week, some experience long-lasting joint pain or severe acute complications, including organ failure.

Ixchiq: A Live Attenuated Vaccine

Ixchiq,a live attenuated vaccine,received approval on June 28,2024,as a single-dose vaccine against Chikungunya. Approximately 43,400 doses have been administered worldwide.

Serious Adverse Events Trigger Review

The PRAC is investigating 17 serious adverse events in vaccinated individuals aged 62 to 89, including two fatalities. Many of these individuals had pre-existing medical conditions. The investigation aims to determine whether a direct link exists between the vaccine and these adverse events.

Temporary Restrictions on Ixchiq Use

Given that initial clinical trials primarily involved individuals under 65 and the reported serious side effects predominantly affected those 65 and older, the EMA security committee is temporarily recommending restricting the vaccine’s use.Ixchiq should not be administered to individuals aged 65 and over. Vaccination can continue for those under 65,following official recommendations.

The PRAC also reiterates that Ixchiq is contraindicated for individuals with weakened immune systems, regardless of age, due to the increased risk of complications associated with live vaccines.

Future Evaluation

The EMA security committee will conduct a thorough evaluation of all available data to reassess the benefits and risks of the Ixchiq vaccine. Based on this evaluation, experts will determine whether the registration conditions for Ixchiq need to be adjusted.This ongoing vigilance underscores the commitment to ensuring the safety and efficacy of pharmaceutical products.